Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Approval is based on positive data from the Phase 3 ECHELON-3 trial
TFOS is indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
